Quidel Corporation (NASDAQ:QDEL) CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $33.83, for a total value of $1,217,880.00. Following the sale, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at $10,030,358.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Quidel Corporation (QDEL) traded up 2.45% during mid-day trading on Friday, hitting $33.40. The stock had a trading volume of 314,044 shares. Quidel Corporation has a 12-month low of $18.25 and a 12-month high of $38.92. The stock’s 50-day moving average price is $31.36 and its 200-day moving average price is $24.95. The stock’s market capitalization is $1.12 billion.
Quidel Corporation (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, July 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.18. Quidel Corporation had a negative net margin of 0.03% and a negative return on equity of 0.03%. The firm had revenue of $38.30 million during the quarter, compared to analyst estimates of $41.91 million. During the same period last year, the firm earned ($0.11) EPS. Quidel Corporation’s quarterly revenue was down 2.0% on a year-over-year basis. On average, equities analysts anticipate that Quidel Corporation will post $0.28 EPS for the current fiscal year.
WARNING: This piece was first published by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://rinconhillneighbors.org/2017/08/13/quidel-corporation-qdel-ceo-douglas-c-bryant-sells-36000-shares-of-stock-updated.html.
Several equities research analysts have recently weighed in on the company. Canaccord Genuity reissued a “hold” rating and set a $25.00 price objective (up from $24.50) on shares of Quidel Corporation in a research note on Friday, May 19th. TheStreet raised Quidel Corporation from a “c+” rating to a “b-” rating in a research note on Thursday, July 6th. BidaskClub cut Quidel Corporation from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 16th. Zacks Investment Research raised Quidel Corporation from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Tuesday, July 18th. Finally, Raymond James Financial, Inc. raised their target price on Quidel Corporation from $36.00 to $41.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Quidel Corporation has an average rating of “Hold” and a consensus price target of $31.40.
Institutional investors have recently made changes to their positions in the company. Acrospire Investment Management LLC raised its position in shares of Quidel Corporation by 42.2% in the second quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock worth $100,000 after buying an additional 1,091 shares during the last quarter. First Mercantile Trust Co. raised its position in shares of Quidel Corporation by 0.8% in the first quarter. First Mercantile Trust Co. now owns 5,280 shares of the company’s stock worth $120,000 after buying an additional 40 shares during the last quarter. Legal & General Group Plc raised its position in shares of Quidel Corporation by 4.6% in the first quarter. Legal & General Group Plc now owns 6,931 shares of the company’s stock worth $157,000 after buying an additional 306 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Quidel Corporation during the second quarter worth $209,000. Finally, First Quadrant L P CA bought a new position in shares of Quidel Corporation during the second quarter worth $217,000. 89.34% of the stock is owned by hedge funds and other institutional investors.
About Quidel Corporation
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with our FREE daily email newsletter.